A Phase I Clinical Trial to Evaluate the Safety and Tolerability of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody IV Infusion in Patients With Malignant Solid Tumors
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs JCXH-211 (Primary) ; Toripalimab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Immorna
- 22 Jan 2025 New trial record